This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CEO Of ProPhase Labs Ups Ad Spend In Response To ESPN On-Air Commentator

Stocks in this article: PRPH

DOYLESTOWN, Pa., May 28, 2014 /PRNewswire/ -- ProPhase Labs, Inc.(NASDAQ: PRPH) today announced their support of ESPN's First Take host, Stephen A. Smith by directing its ad agency to increase advertising of its products on both ESPN and ESPN2.

In response to Stephen A. Smith's speech on Friday, May 23rd regarding race, role models and the American Dream, Ted Karkus, ProPhase Labs' Chairman and CEO, has decided to increase the ad spend in an effort to support the commentators overall, insightful message to America's youth.

"The speech that Stephen A. Smith gave on Friday was not only a motivating one, but provides guidance for all youth in our country," says Ted Karkus. "Usually you hear about sponsors 'pulling the plug' when a commentator says something inappropriate.  In this case, I thought to do the opposite, i.e. increase our ad spend to support a speech that literally brought tears to my eyes. Being a CEO of a nationally recognized brand, I understand the obstacles and the hard work it takes to achieve one's dreams. While Stephen's speech primarily targeted underprivileged minorities, it was truly a speech that transcended race.  It was a message for the youth of America to work hard, become educated, show respect for others and present yourself appropriately so that success can become a reality as opposed to the one out of a billion possibility of becoming the next Lebron or Jay Z.  My wife taped the speech and the first thing I did was replay it for my children.  I am proud to be an advertiser on ESPN and ESPN2 and look forward to flourishing my relationship with the network and its personalities."  

ProPhase Labs is an OTC pharmaceutical company based in Doylestown, PA. and has been advertising with ESPN for the past 3 years. For more information on ProPhase Labs and Ted Karkus, please visit ProPhaseLabs.com.

About ProPhase LabsProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE ® Cold Remedy brand as well as other cold relief products.  Cold-EEZE ® Cold Remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold.  Cold-EEZE ® Cold Remedy customers include leading national chain, regional, specialty and local retail stores.  ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE ® Cold Remedy lozenges and fulfill other contract manufacturing opportunities.  ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion").  Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds.  Phusion will formulate and test products to exploit market opportunities within ProPhase's robust over-the-counter distribution channels.   For more information visit us at www.ProPhaseLabs.com.

SOURCE ProPhase Labs, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,355.30 -25.11 -0.15%
S&P 500 1,896.91 +10.15 0.54%
NASDAQ 4,295.8710 +37.4330 0.88%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs